Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina

Autores
Córdoba, Susana; Isla, Maria G; Szusz, Wanda; Vivot, Walter; Altamirano, Rodrigo; Davel, Graciela Odelsia
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina.
Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested.
Fuente
Mycoses 2016; 59(6):351-6.
Materia
Argentina
Cryptococcus neoformans
VIH
Nivel de accesibilidad
acceso abierto
Condiciones de uso
none
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:Publications/123456789/2106

id SGCANLIS_cf1a4dc485cea75b7b0c76e0d232d32f
oai_identifier_str oai:sgc.anlis.gob.ar:Publications/123456789/2106
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from ArgentinaCórdoba, SusanaIsla, Maria GSzusz, WandaVivot, WalterAltamirano, RodrigoDavel, Graciela OdelsiaArgentinaCryptococcus neoformansVIHFil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina.Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested.Wiley2016-06info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1439-0507https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479http://sgc.anlis.gob.ar/handle/123456789/210610.1111/myc.12479Mycoses 2016; 59(6):351-6.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISMycosesnoneinfo:eu-repo/semantics/openAccesseng2025-11-06T10:11:01Zoai:sgc.anlis.gob.ar:Publications/123456789/2106Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-11-06 10:11:01.977Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
title Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
spellingShingle Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
Córdoba, Susana
Argentina
Cryptococcus neoformans
VIH
title_short Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
title_full Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
title_fullStr Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
title_full_unstemmed Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
title_sort Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina
dc.creator.none.fl_str_mv Córdoba, Susana
Isla, Maria G
Szusz, Wanda
Vivot, Walter
Altamirano, Rodrigo
Davel, Graciela Odelsia
author Córdoba, Susana
author_facet Córdoba, Susana
Isla, Maria G
Szusz, Wanda
Vivot, Walter
Altamirano, Rodrigo
Davel, Graciela Odelsia
author_role author
author2 Isla, Maria G
Szusz, Wanda
Vivot, Walter
Altamirano, Rodrigo
Davel, Graciela Odelsia
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Argentina
Cryptococcus neoformans
VIH
topic Argentina
Cryptococcus neoformans
VIH
dc.description.none.fl_txt_mv Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Isla, Maria G. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Szusz, Wanda. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Vivot, Walter. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Fil: Altamirano, Rodrigo. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina. Cátedra de Cálculo Estadístico y Biometría, Facultad de Ciencias Agrarias y Forestales, Buenos Aires; Argentina.
Fil: Davel, Graciela. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
Epidemiological cut-off values (ECVs) based on minimal inhibitory concentration (MIC) distribution have been recently proposed for some antifungal drug/Cryptococcus neoformans combinations. However, these ECVs vary according to the species studied, being serotypes and the geographical origin of strains, variables to be considered. The aims were to define the wild-type (WT) population of the C. neoformans species complex (C. neoformans) isolated from patients living in Argentina, and to propose ECVs for six antifungal drugs. A total of 707 unique C. neoformans isolates obtained from HIV patients suffering cryptococcal meningitis were studied. The MIC of amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole was determined according to the EDef 7.2 (EUCAST) reference document. The MIC distribution, MIC50 , MIC90 and ECV for each of these drugs were calculated. The highest ECV, which included ≥95% of the WT population modelled, was observed for flucytosine and fluconazole (32 μg ml(-1) each). For amphotericin B, itraconazole, voriconazole and posaconazole, the ECVs were: 0.5, 0.5, 0.5 and 0.06 μg ml(-1) respectively. The ECVs determined in this study may aid in identifying the C. neoformans strains circulating in Argentina with decreased susceptibility to the antifungal drugs tested.
description Fil: Córdoba, Susana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.
publishDate 2016
dc.date.none.fl_str_mv 2016-06
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 1439-0507
https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479
http://sgc.anlis.gob.ar/handle/123456789/2106
10.1111/myc.12479
identifier_str_mv 1439-0507
10.1111/myc.12479
url https://onlinelibrary.wiley.com/doi/abs/10.1111/myc.12479
http://sgc.anlis.gob.ar/handle/123456789/2106
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Mycoses
dc.rights.none.fl_str_mv none
info:eu-repo/semantics/openAccess
rights_invalid_str_mv none
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Mycoses 2016; 59(6):351-6.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1848048320970227712
score 12.576249